Virus News and Research

Latest Virus News and Research

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

20 Oct 2009

Alberta revises its cervical cancer screening guideline

Alberta has revised its Cervical Cancer Screening Clinical Practice Guideline (CPG) based on new technologies and epidemiologic evidence from Alberta and internationally.

20 Oct 2009

Unitedhealth announces third quarter results; reports growth in revenues and net earnings

UnitedHealth Group reported third quarter results today, including growth in revenues and net earnings and a continued strong financial position.

20 Oct 2009

Coworkers should remain home if infected with H1N1 flu virus, says majority of Americans

91 per cent of Americans said they want their co-workers to remain at home if they are infected with the H1N1 flu virus according to a national survey released today by Mansfield Communications.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

Swine flu outbreak at USAFA: Investigators study behavior of the nH1N1 virus

With the 2009 influenza season upon us, characterization of the epidemiology and duration of shedding for the nH1N1 virus is critical. Investigators from the U.S. Air Force Academy and the U.S. Air Force School of Aerospace Medicine Epidemiology Consult Service capitalized on a unique opportunity to gain valuable insights about the natural behavior of the nH1N1 virus, including shedding patterns, during a recent large-scale swine flu outbreak at the U.S. Air Force Academy (USAFA).

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.

20 Oct 2009

Novel H1N1 influenza raises parents' awareness and concern about seasonal influenza

Novel H1N1 influenza has raised parents' awareness and concern about seasonal influenza, increasing the likelihood that they will get their children vaccinated compared to past years, according to a recent national survey commissioned by the National Foundation for Infectious Diseases (NFID).

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

California's community hospitals launch public education and media campaign on H1N1

As preparations for the H1N1 flu season kick into high gear, California's community hospitals have launched a statewide public education and media campaign.

19 Oct 2009

WHO recommends antivirals for patients with symptoms of both H1N1, pneumonia

The WHO concluded a three-day meeting on H1N1 (swine flu) in Washington, D.C., on Friday, where health experts issued recommendations that patients with symptoms of H1N1 and pneumonia be treated quickly with antivirals, even before the results of H1N1 tests are complete, the San Francisco Chronicle blog, "ChronRX" reports (Allday, 10/16).

19 Oct 2009

Experts: Treat swine flu quickly, even without verification

The World Health Organization concluded a three-day meeting on H1N1 (swine flu) in Washington, D.C., on Friday, where health experts issued recommendations that patients with symptoms of H1N1 and pneumonia be treated quickly with antivirals, even before the results of H1N1 tests are complete, the San Francisco Chronicle blog, "ChronRX" reports (Allday, 10/16).

19 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Virus News and Research

Latest Virus News and Research

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

Alberta revises its cervical cancer screening guideline

Unitedhealth announces third quarter results; reports growth in revenues and net earnings

Coworkers should remain home if infected with H1N1 flu virus, says majority of Americans

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Swine flu outbreak at USAFA: Investigators study behavior of the nH1N1 virus

Biomagnetics Diagnostics to raise $1 million

Cangene to acquire U.S. commercialization rights for HepaGam B

Fluarix seasonal influenza vaccine approved by the FDA

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Novel H1N1 influenza raises parents' awareness and concern about seasonal influenza

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

California's community hospitals launch public education and media campaign on H1N1

WHO recommends antivirals for patients with symptoms of both H1N1, pneumonia

Experts: Treat swine flu quickly, even without verification

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in